摘要
目的探讨维持性血液透析患者C反应蛋白变化,以及洛伐他汀对其的影响。方法维持性血液透析患者20例,洛伐他汀剂量20 mg/d口服,观察12周;观察指标包括血总胆固醇、甘油三酯、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HLD-C)、血C反应蛋白、白蛋白。结果维持性血液透析组治疗前C反应蛋白水平升高,使用洛伐他汀12周后血总胆固醇、甘油三酯、LDL-C均明显降低,而HDL-C上升,C反应蛋白从治疗前(10.83±3.0)mg/L降至(7.78±2.16)mg/L(P<0.05)。血白蛋白经洛伐他汀12周治疗后上升,从治疗前(32.47±4.65)g/L上升至(34.47±6.78)g/L(P<0.05),白蛋白上升与血C反应蛋白下降呈负相关(r=-0.305,P<0.05)。结论维持性血液透析患者存在微炎症状态,洛伐他汀对维持性血液透析患者除降脂外,还具有抗炎作用,能明显降低血C反应蛋白水平。
Objective To explore the changes of C-reactive protein and the influence of lovastatin in hemodialysis patients. Methods Twenty hemodialysis patients,administered orally lovastatin 20 mg/d for 12 weeks. Observation index includes： total cholesterol, triglyeeride, lower density lipo-protein cholesterol （LDL-C）, high density lipo-protein choleseerol （ HDL-C）, C-reactive protein, albumin. Results In the hemodialysis groups, the levels of C-reactive protein increased. Lovastatin administration for 12 weeks significantly redueed total eholesterol,triglyeeride, LDL-C,and increased HDL-C. The levels of C-reactive protein decreased obviously form （10.83±3.0） mg/L to （7.78 ± 2.16） mg/L at 12 weeks（ P 〈0.05）. Whereas increased serum albumin levels from （32. 47±4.65） g/L to （34.47±6.78） g/L at 12 weeks （P 〈0.05）. The negative relationship between serum albumin levels and serum C-reactive protein levels was significant （ r =--0. 305, P〈 0.05）. Conclusion The mieroinflammatory state is present in hemodialysis patients. Lovastatin exhibits comparable favourable effects on lipid profiles in hemodialysis patients. Moreover,the reduction of serum C-reactive protein levels as shown in our investigation may indicate that lovastatin exhibits favourable effects on mieroinflammation.
出处
《临床荟萃》
CAS
北大核心
2006年第12期856-858,共3页
Clinical Focus
